BNR

Burning Rock Biotech Limited (NASDAQ:BNR) is a Chinese precision oncology company founded in 2014 and headquartered in Guangzhou, China. The company went public on NASDAQ in June 2020. Burning Rock specializes in developing and providing cancer diagnostics and therapy selection tests using next-generation sequencing (NGS) technology. The company has evolved from primarily operating central laboratory services to increasingly focusing on in-hospital testing solutions and pharmaceutical research services, positioning itself as a key player in China's growing precision medicine market.